Vigil Neuroscience supplements proxy disclosures in response to 16 stockholder demands regarding Sanofi merger

Vigil Neuroscience, Inc.

Received 16 demands from June 18 to July 28, 2025, alleging omissions in definitive proxy statement for pending Sanofi merger.
Voluntarily supplements disclosures including Centerview's discount rate rationale (15%-16.5% WACC) and CVR risk-adjusted NPV of $0.14 per CVR.
Adds details on analyst price targets ($11-$22 per share, median $16) and precedent premiums (80%-200% applied to $2.48 closing price).
Updates projected equity raises: $80M in H2 2025 and $1.3B in 2026-2030 for capital requirements.
No admission of wrongdoing; company believes proxy statement complies with law and intends to vigorously defend.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.